Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Army
Chubb
US Department of Justice
Fuji
Julphar
Novartis
Dow
AstraZeneca
QuintilesIMS
Deloitte

Generated: October 22, 2017

DrugPatentWatch Database Preview

Par Pharm Company Profile

« Back to Dashboard

What is the competitive landscape for PAR PHARM, and when can generic versions of PAR PHARM drugs launch?

PAR PHARM has two hundred and twelve approved drugs.

There is one US patent protecting PAR PHARM drugs on PAR PHARM drugs in the past three years. There are fourteen tentative approvals on PAR PHARM drugs.

There are nine patent family members on PAR PHARM drugs in eight countries and one hundred and fifteen supplementary protection certificates in twelve countries.

Summary for Applicant: Par Pharm

International Patents:9
US Patents:1
Tradenames:125
Ingredients:122
NDAs:212
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Par Pharm
FENTANYL CITRATE
fentanyl citrate
TROCHE/LOZENGE;TRANSMUCOSAL077312-005Oct 30, 2009ABRXNoNo► Subscribe► Subscribe► Subscribe
Par Pharm
CAPOTEN
captopril
TABLET;ORAL018343-003Approved Prior to Jan 1, 1982DISCNYesNo► Subscribe► Subscribe► Subscribe
Par Pharm
OXYMORPHONE HYDROCHLORIDE
oxymorphone hydrochloride
TABLET, EXTENDED RELEASE;ORAL200792-003Oct 24, 2014DISCNNoNo► Subscribe► Subscribe► Subscribe
Par Pharm
PROPRANOLOL HYDROCHLORIDE
propranolol hydrochloride
TABLET;ORAL071288-001Oct 22, 1986DISCNNoNo► Subscribe► Subscribe► Subscribe
Par Pharm
OXYMORPHONE HYDROCHLORIDE
oxymorphone hydrochloride
TABLET, EXTENDED RELEASE;ORAL200792-006Oct 24, 2014DISCNNoNo► Subscribe► Subscribe► Subscribe
Par Pharm Inc
MORPHINE SULFATE
morphine sulfate
CAPSULE, EXTENDED RELEASE;ORAL200812-001Nov 10, 2011ABRXNoNo► Subscribe► Subscribe► Subscribe
Par Pharm
CAPTOPRIL
captopril
TABLET;ORAL074493-004Feb 13, 1996DISCNNoNo► Subscribe► Subscribe► Subscribe
Par Pharm
AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE
amlodipine besylate; benazepril hydrochloride
CAPSULE;ORAL078381-005Jul 29, 2010ABRXNoNo► Subscribe► Subscribe► Subscribe
Par Pharm
FENTANYL CITRATE
fentanyl citrate
TROCHE/LOZENGE;TRANSMUCOSAL077312-002Oct 30, 2009ABRXNoNo► Subscribe► Subscribe► Subscribe
Par Pharm
OXYMORPHONE HYDROCHLORIDE
oxymorphone hydrochloride
TABLET, EXTENDED RELEASE;ORAL200792-007Oct 24, 2014DISCNNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Par Pharm

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Par Pharm Inc
ACCOLATE
zafirlukast
TABLET;ORAL020547-001Sep 26, 1996► Subscribe► Subscribe
Par Pharm
CAPOTEN
captopril
TABLET;ORAL018343-002Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Par Pharm Inc
ACCOLATE
zafirlukast
TABLET;ORAL020547-001Sep 26, 1996► Subscribe► Subscribe
Par Pharm
CAPOTEN
captopril
TABLET;ORAL018343-004Jun 13, 1995► Subscribe► Subscribe
Par Pharm
CAPOTEN
captopril
TABLET;ORAL018343-004Jun 13, 1995► Subscribe► Subscribe
Par Pharm
CAPOTEN
captopril
TABLET;ORAL018343-003Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Par Pharm Inc
ACCOLATE
zafirlukast
TABLET;ORAL020547-003Sep 17, 1999► Subscribe► Subscribe
Par Pharm
NASCOBAL
cyanocobalamin
GEL, METERED;NASAL019722-001Nov 5, 1996► Subscribe► Subscribe
Par Pharm
CAPOTEN
captopril
TABLET;ORAL018343-001Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Par Pharm Inc
ACCOLATE
zafirlukast
TABLET;ORAL020547-003Sep 17, 1999► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for PAR PHARM drugs

Drugname Dosage Strength Tradename Submissiondate
cyanocobalamin
Nasal Spray500 mcg/spray
NASCOBAL
4/28/2017
zafirlukast
Tablets10 mg and 20 mg
ACCOLATE
2/29/2008

International Patent Family for Par Pharm Drugs

Country Document Number Estimated Expiration
European Patent Office1948613► Subscribe
World Intellectual Property Organization (WIPO)2006115626► Subscribe
South Korea20080000660► Subscribe
China101163679► Subscribe
Japan5378788► Subscribe
Australia2006240490► Subscribe
Mexico2007013118► Subscribe
Canada2605413► Subscribe
Japan2008538560► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Par Pharm Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB97/088United Kingdom► SubscribePRODUCT NAME: TOLCAPONE; REGISTERED: CH 54055/01 19970225; CH 54055/02 19970225; UK EU/1/97/044/001 19970827; UK EU/1/97/044/002 19970827; UK EU/1/97/044/003 19970827; UK EU/1/97/044/004 19970827; UK EU/1/97/044/005 19970827; UK EU/1/97/044/006 19970827
70015Netherlands► SubscribePRODUCT NAME: OLANZAPINE, DESGEWENST IN DE VORM VAN EEN ZUURADDITIEZOUT; REGISTRATION NO/DATE: EU/1/96/022/001 - EU/1/96/022/010 19960927
C/GB99/008United Kingdom► SubscribePRODUCT NAME: 2-N-BUTYL-4-SPIROCYCLOPENTANE-1-((2'-(TETRAZOL-5-YL)BIPHENYL-4-YL)METHYL)-2-IMIDAZOLIN-5-ONE)(GENERIC NAME IRBESARTAN) OPTIONALLY IN THE FORM OF ONE OF ITS SALTS AND HYDROCHLOROTHIAZIDE; REGISTERED: UK EU/1/98/086/001 19981015; UK EU/1/98/086/002 19981015; UK EU/1/98/086/003 19981015; UK EU/1/98/086/004 19981015; UK EU/1/98/086/005 19981015; UK EU/1/98/086/006 19981015
14/032Ireland► SubscribePRODUCT NAME: DOLUTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE THEREOF, INCLUDING DOLUTEGRAVIR SODIUM; REGISTRATION NO/DATE: EU/1/13/892/001-002 20140121
C0045France► SubscribePRODUCT NAME: TRAVOPROST; REGISTRATION NO/DATE: EU/1/01/199/001 20011127
315Luxembourg► SubscribePRODUCT NAME: COMBINAISON COMPRENANT ALISKIREN,OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLE,ET AMLODIPINE,OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLE
91023-9Sweden► SubscribePRODUCT NAME: ROSUVASTATIN
2006000022Germany► SubscribePRODUCT NAME: TRANSDERMAL IONTOPHORETISCH VERABREICHTES FENTANYL-HYDROCHLORID; REGISTRATION NO/DATE: EU/1/05/326/001 20060126
C0033France► SubscribePRODUCT NAME: ALISKIRENE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE E CELUI-CI, AMLODIPINE OU SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI, ET HYDROCHLOROTHIAZIDE OU SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; NAT. REGISTRATION NO/DATE: EU/1/11/730/001 20111122; FIRST REGISTRATION: 6167801 20110705
07C/043Belgium► SubscribePRODUCT NAME: AMLODIPINE ET VALSARTAN; NATL. REGISTRATION NO/DATE: EU/1/06/370/001 20070118; FIRST REGISTRATION: CH 57771 20061222
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

McKesson
Healthtrust
Argus Health
Farmers Insurance
Federal Trade Commission
UBS
Citi
Cantor Fitzgerald
Queensland Health
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot